Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate OnKure Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding OnKure Therapeutics, Inc.’s stock price such as:

• OnKure Therapeutics, Inc.’s current stock price and volume
• Why OnKure Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for OKUR from analysts
• OKUR’s stock price momentum as measured by its relative strength

About OnKure Therapeutics, Inc. (OKUR)

Before we jump into OnKure Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.

Want to learn more about OnKure Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about OnKure Therapeutics, Inc..

OnKure Therapeutics, Inc.’s Stock Price as of Market Close

As of September 11, 2026, 4:00 PM, CST, OnKure Therapeutics, Inc.’s stock price was $3.100.

OnKure Therapeutics, Inc. is down 5.2% from its previous closing price of $3.270.

During the last market session, OnKure Therapeutics, Inc.’s stock traded between $2.980 and $3.330. Currently, there are approximately 49.87 million shares outstanding for OnKure Therapeutics, Inc..

OnKure Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

OnKure Therapeutics, Inc. Stock Price History

OnKure Therapeutics, Inc.’s (OKUR) price is currently down 14.6% so far this month.

During the month of September, OnKure Therapeutics, Inc.’s stock price has reached a high of $3.900 and a low of $2.980.

Over the last year, OnKure Therapeutics, Inc. has hit prices as high as $5.380 and as low as $2.230. Year to date, OnKure Therapeutics, Inc.’s stock is up 6.9%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused OnKure Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 11, 2026, there were 0 analysts who downgraded OnKure Therapeutics, Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate OnKure Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on OnKure Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

OnKure Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about OnKure Therapeutics, Inc. (OKUR) by visiting AAII Stock Evaluator.

Relative Price Strength of OnKure Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 11, 2026, OnKure Therapeutics, Inc. has a weighted four-quarter relative price strength of -1.68%, which translates to a Momentum Score of 49 and is considered to be Average.

Want to learn more about how OnKure Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

OnKure Therapeutics, Inc. Stock Price: Bottom Line

As of September 11, 2026, OnKure Therapeutics, Inc.’s stock price is $3.100, which is down 5.2% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like OnKure Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.